Collins Helen Louise's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Apr 21, 2026
- Accession no.
- 0001701247-26-000006
- Filed
- Apr 21, 2026
- Trade date
- Apr 17, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $238.4K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Collins Helen LouiseCIK 0001701247 | Officer (CHIEF MEDICAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 17, 2026 | Common Stock | MOption exerciseAcquired | +5,000 | $2.48 | +$12,400 | 30,000 | Direct | |
| Apr 17, 2026 | Common Stock | SSaleDisposed | −140 | $45.81F3 | −$6,413.4 | 29,860 | Direct | |
| Apr 17, 2026 | Common Stock | SSaleDisposed | −2,419 | $47.39F4 | −$114,636.41 | 27,441 | Direct | |
| Apr 17, 2026 | Common Stock | SSaleDisposed | −2,441 | $48.06F5 | −$117,314.46 | 25,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 17, 2026 | Common Stock | MOption exerciseDisposed | −5,000 | $0.00 | $0 | 131,268 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $45.525 to $46.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $46.8218 to $47.8166. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $47.8303 to $48.4936. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.